Abstract 3310
Background
Circulating tumor DNA (ctDNA) is a minimally-invasive technique to profile the tumor genome in different cancers but is still underexplored in squamous cell carcinoma of the head and neck (SCCHN). Our aim was to study the relevance of mutational profiling through liquid biopsy in SCCHN.
Methods
We collected plasma cell-free DNA from 39 patients (pts) with locoregional recurrent (LR) (n = 19) and/or metastatic (M) (n = 20) SCCHN. Targeted next-generation sequencing (Illumina, HiSeq4000) was performed on a custom panel of 604 genes (median coverage 1000x). When available (n = 18), a tumor biopsy was sequenced to evaluate the concordance of somatic mutations.
Results
M SCCHN pts had a higher probability of carrying ctDNA than LR pts (70% vs 31%, p = 0.0256). When ctDNA was detected, the quantity (estimated using the median of the allele frequencies (AF) of all the somatic plasma variants) did not differ between the two groups (median 2.3% vs 2.6%, p = 0.97). The concordance between liquid and solid biopsy showed that 26% of the plasma variants (14/54) were not detected in the matched tumors, reflecting some tumor heterogeneity. Conversely, 81% of the variants (168/208) identified in the solid tumors were not detected in the plasma. In a logistic regression model, the detection of the variant in the plasma was related to the metastatic status (Odds Ratio (OR) 4.50, p = 0.012), the variant AF in the tumor (OR = 5.31, p < 0.001) and the ctDNA quantity (OR = 4.13, p < 0.001). Classification of the variant as a driver or passenger based on TCGA and COSMIC was however not relevant (OR = 1.05, p = 0.948). As expected, TP53 was the most frequently mutated gene, both in liquid and solid biopsy. Of clinical interest, the plasma of 3 pts for whom no tumor was available carried 3 different potentially actionable PIK3CA mutations, including the hotspot E545K.
Conclusions
Detection of ctDNA using targeted NGS is feasible in pts with SCCHN, essentially for metastatic disease. Liquid biopsy alone can identify potentially actionable alterations but does not reflect the full landscape of the solid tumor. Presence of a solid tumor variant in the plasma is related to the variant AF, the metastatic status and the ctDNA quantity of the sample.
Clinical trial identification
NCT02139020.
Editorial acknowledgement
Legal entity responsible for the study
Cliniques Universitaires Saint-Luc - Université Catholique de Louvain, Brussels, Belgium.
Funding
Région Wallonne, Belgium - Fondation Louvain UCLouvain.
Disclosure
R. Galot: Advisory / Consultancy: Innate Pharma; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Amgen. J. Machiels: Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Innate Pharma; Honoraria (institution), Research grant / Funding (institution): Merck Serono; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (institution), Research grant / Funding (institution): Novartis; Honoraria (institution), Research grant / Funding (institution): Janssen; Honoraria (institution), Research grant / Funding (institution): Incyte; Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution), Travel / Accommodation / Expenses, Uncompensated advisory role: MSD; Advisory / Consultancy, Data safety monitoring board with honoraria: Debio; Advisory / Consultancy, Data safety monitoring board with honoraria: Nanobiotix; Non-remunerated activity/ies, investigator and study coordinator: EORTC. All other authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract